DEXAD

The DEXAD clinical trial is investigating the safety and efficacy of dexamfetamine sulfate in adults with ADHD and moderate to severe depression.

Attention deficit hyperactivity disorder (ADHD) is particularly common in adults with depression. Data from several studies indicate that certain active ingredients used to treat ADHD may also improve depression. This study therefore aims to investigate the active ingredient dexamfetamine for this purpose.

For this study we are looking for

Patients with existing ADHD since childhood (<12 years) and a diagnosis of moderate to severe depression
Aged between 18 and 65 years
BMI > 18.5 kg/m² and 35 kg/m²
Not pregnant or breastfeeding
No uncontrolled or severe pre-existing conditions
No psychotic symptoms, schizophrenia, bipolar disorder, or manic episodes
No drug abuse within the last 6 months

study procedure

To test the active ingredient, you will be randomly assigned to one of three study groups (two treatment groups receiving dexamfetamine and one control group receiving a placebo).

At the beginning, you will be given the optimal dosage, which you will then take weekly for 12 weeks.

Finally, there will be a follow-up examination.

Participation lasts a total of 19 weeks with 8-11 visits to the trial site, where your health status will be assessed using questionnaires. An ECG will also be performed and laboratory values, blood pressure, and pulse will be measured.

What are you gaining from this procedure?

For your participation, you will receive an expense allowance of €20 per visit (max. €220). You will receive medical examinations and intensive care from the study staff. In addition, your depression may improve, and you will be supporting medical research and helping other people affected by depression.